Back to News
Market Impact: 0.3
Intellia Eyes Lonvo-z Launch as HAE PDUFA Nears, TTR Study Advances
Source: marketbeat.com
Healthcare & BiotechCorporate Guidance & OutlookCompany Fundamentals
Intellia Therapeutics outlined potential launch preparations for lonvo-z, its hereditary angioedema treatment, at a Morgan Stanley event. Management also highlighted the ongoing Phase III program in transthyretin amyloidosis and discussed its capital position, signaling continued advancement of its clinical pipeline but providing no new efficacy, regulatory, or financial figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
NTLA0.35
More News
- Boeing Isn't Perfect -- but It's Still a Compelling Value Buy Right Now
- 26 Analysts Covering SpaceX Stock Rate It a Buy. Here's Why 8 Analysts Disagree
- After a Long Hiatus, Crypto ETFs Are Making a Comeback. Here's the 1 Crypto ETF You Need to Own.
- Higher interest rates and AI safety fears put the stock market to the test last week
- AI safety efforts will require more compute, not less: experts
- Buffett Son Takes Chair as Berkshire Transition Ends